Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

SIMPLE SUMMARY: Children with T-cell leukemia (T-ALL) who experience relapse have a low chance of a cure with current therapy; so, new medicines are needed. MERTK and BCL-2 are proteins that may be therapeutic targets in children with T-ALL. In this research we tested whether treatments targeting ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Summers, Ryan J., Jain, Juhi, Vasileiadi, Eleana, Smith, Brittany, Chimenti, Madison L., Yeung, Tsz Y., Kelvin, James, Wang, Xiaodong, Frye, Stephen V., Earp, H. Shelton, Tyner, Jeffrey W., Dreaden, Erik C., DeRyckere, Deborah, Graham, Douglas K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776749/
https://www.ncbi.nlm.nih.gov/pubmed/36551626
http://dx.doi.org/10.3390/cancers14246142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776749/
https://www.ncbi.nlm.nih.gov/pubmed/36551626
http://dx.doi.org/10.3390/cancers14246142

Ejemplares similares